Akoya Biosciences Inc

NASDAQ AKYA

Download Data

Akoya Biosciences Inc Operating Income to Total Debt 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 26.74%

Akoya Biosciences Inc Operating Income to Total Debt 1 year YoY Change (%) is 26.74% for the Trailing 12 Months (TTM) ending March 31, 2024, a 36.75% change year over year. The operating income to total debt ratio measures the ability of a company's operating income to cover its total debt obligations. It is calculated by dividing the operating income by the total debt. This ratio provides insights into the company's ability to generate income from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating income relative to the level of debt, suggesting potential financial strength and debt servicing capability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Akoya Biosciences Inc Operating Income to Total Debt for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.29, a 19.55% change year over year.
  • Akoya Biosciences Inc Operating Income to Total Debt for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.37, a -198.79% change year over year.
  • Akoya Biosciences Inc Operating Income to Total Debt for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.12.
NASDAQ: AKYA

Akoya Biosciences Inc

CEO Mr. Brian McKelligon
IPO Date April 16, 2021
Location United States
Headquarters 100 Campus Drive, Marlborough, MA, United States, 01752
Employees 330
Sector Healthcare
Industry Medical instruments & supplies
Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

PDEX

Pro-Dex Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email